曲妥珠单抗-帕妥珠单抗联合艾日布林或多西他赛作为人表皮生长因子受体2阳性局部晚期/转移性乳腺癌一线化疗:随机非劣效III期EMERALD试验
EMERALD III期随机非劣效试验纳入446例HER2阳性局部晚期/转移性乳腺癌患者,1:1接受艾日布林或紫杉类联合曲妥珠单抗-帕妥珠单抗一线治疗。艾日布林组中位无进展生存期14.0个月 vs 紫杉类组12.9个月(HR 0.95,95%CI 0.76-1.19),证实非劣效;总生存紫杉类组65.3个月,艾日布林组未达到。结论提示艾日布林联合曲妥珠单抗-帕妥珠单抗是HER2阳性局部晚期/转移性乳腺癌一线治疗的选择。
要点
- 艾日布林联合HP一线治疗HER2阳性局部晚期/转移性乳腺癌,中位PFS 14.0个月 vs 紫杉类联合HP 12.9个月,HR 0.95(95%CI 0.76-1.19),证实非劣效。
- 紫杉类组中位OS为65.3个月,艾日布林组未达到。
- 艾日布林组中性粒细胞减少更常见,紫杉类组输注反应、皮肤相关不良事件、腹泻和水肿更常见。
核心结论
- 结果提示艾日布林联合曲妥珠单抗-帕妥珠单抗是HER2阳性局部晚期/转移性乳腺癌一线治疗的一个选择。
研究设计与样本
- III期EMERALD随机非劣效试验(目标样本量480例;ClinicalTrials.gov NCT03264547/UMIN000027938),2017年8月至2021年6月入组446例患者(中位年龄56.0岁),1:1随机分配。
- 艾日布林组(n=224)接受艾日布林1.4 mg/m2,第1天和第8天每日一次静脉给药;紫杉类组(n=222,其中多西他赛186例/紫杉醇36例)接受多西他赛75 mg/m2第1天一次或紫杉醇80 mg/m2第1、8、15天每日一次静脉给药;21天为一周期,每组第1天联合曲妥珠单抗-帕妥珠单抗。
- 主要终点为意向治疗人群的无进展生存期(PFS);次要终点包括客观缓解率、总生存期(OS)、患者报告的生活质量(QoL)和安全性;非劣效界值HR为1.33,采用分层Cox比例风险模型估计PFS事件的风险比(HR)。
主要发现
- 艾日布林组中位PFS为14.0个月,紫杉类组为12.9个月(HR 0.95,95%CI 0.76-1.19),证实研究方案的非劣效性。
- 紫杉类组中位OS为65.3个月,艾日布林组未达到。
- 艾日布林组生活质量恶化中位时间数值上长于紫杉类组。
- 不良事件发生率相似,尽管艾日布林使用时间更长;输注反应、皮肤相关不良事件、腹泻和水肿在紫杉类组更常见,而中性粒细胞减少在艾日布林组更常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC. METHODS: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.gov identifier: NCT03264547/UMIN000027938), patients were randomly assigned (1:1) to receive eribulin 1.4 mg/m2 once daily on days 1 and 8 (eribulin group) or a taxane (docetaxel 75 mg/m2 once on day 1 or paclitaxel 80 mg/m2 once daily on days 1, 8, and 15; taxane group) intravenously in a 21-day cycle, each with HP on day 1. The primary end point was progression-free survival (PFS; intention-to-treat population). Secondary end points included objective response rate, overall survival (OS), patient-reported quality of life (QoL), and safety. Noninferiority was tested using the stratified Cox proportional hazards model to estimate hazard ratios (HRs) for PFS events, with a noninferiority HR margin of 1.33. RESULTS: Between August 2017 and June 2021, 446 patients (median age, 56.0 years) were enrolled. The median PFS was 14.0 and 12.9 months in the eribulin group (n = 224) and taxane group (n = 222 [docetaxel/paclitaxel, n = 186/36]), respectively (HR, 0.95 [95% CI, 0.76 to 1.19]), which confirmed the noninferiority of the study regimen. The median OS was 65.3 months in the taxane group but has not been reached in the eribulin group. Median time to QoL deterioration was numerically longer with eribulin than with taxane. Adverse event (AE) rates were similar, despite the longer duration of eribulin use. Infusion reaction, skin-related AEs, diarrhea, and edema were more common with taxane, whereas neutropenia was more common with eribulin. CONCLUSION: The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.
引用
- Yamashita T, Saji S, Takano T, et al. Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. J Clin Oncol. 2025. PMID: 39787453. doi:10.1200/JCO-24-01888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。